Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

December 15, 2026

Study Completion Date

December 15, 2026

Conditions

Glioma

Interventions

DRUG

Irinotecan liposome combined with bevacizumab

Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;

Trial Locations (1)

RECRUITING

The central Hospital of Lishui City, Lishui

All Listed Sponsors

lead

Zhifeng Tian,MD

OTHER